ArticleCureus2026
Successful Treatment of Refractory Palmoplantar Pustulosis With Bimekizumab in a Patient With Multiple Sclerosis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a case of refractory palmoplantar pustulosis (PPP) in a female in her early 50s with a history of well-controlled multiple sclerosis (MS). PPP is a dermatological condition characterized by chronic pustules often accompanied by fissures on the palms of the hands or soles of the feet. It is often seen in association with psoriasis vulgaris and arthritis; however, it can also present as isolated lesions. Although several treatment options exist for PPP, including topical corticosteroids, topical calcineurin inhibitors, vitamin D analogs, narrowband ultraviolet B (NBUVB) phototherapy, biologics, and topical retinoids, PPP remains a complex disease to treat. In this case, the patient failed to achieve significant improvement despite trialing multiple therapies, including topical corticosteroids, topical agents, systemic therapy, NBUVB phototherapy, and several biologics, as well as adjunctive antifungal therapy, with persistent pain secondary to fissuring and scaling of her plantar skin. Due to the refractory nature of her PPP, bimekizumab, an anti-IL-17A and IL-17F antibody therapy, was administered as a subcutaneous injection at weeks 0, 4, 8, 12, and 16, followed by maintenance dosing every eight weeks. The patient experienced a significant and sustained improvement in her PPP. Although bimekizumab is primarily used to treat psoriasis and psoriatic arthritis, this case highlights its potential role in the treatment of refractory PPP. There are concerns regarding the safety of biologic treatment in patients with MS due to the possibility of worsening MS symptoms. However, these concerns are primarily associated with anti-tumor necrosis factor therapies and may not be directly applicable to IL-17 inhibitors such as bimekizumab. This clinical case suggests that bimekizumab may be a reasonable therapeutic option in patients with well-controlled MS, though further studies are needed to better characterize its safety in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.